EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEG
Previous Symbol
CUSIPN/A
Phone781-788-8869
Debt
Debt-to-Equity RatioN/A
Current Ratio2.55
Quick Ratio2.55
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$410,000.00
Price / Sales60.39
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book2.19
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-13,210,000.00
Net MarginsN/A
Return on Equity-178.01%
Return on Assets-81.45%
Miscellaneous
Employees17
Outstanding Shares43,440,000
Market Cap$23.02 million
OptionableNot Optionable
Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions
What is Eyegate Pharmaceuticals' stock symbol?
Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."
How were Eyegate Pharmaceuticals' earnings last quarter?
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) announced its earnings results on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The specialty pharmaceutical company earned $0.32 million during the quarter, compared to the consensus estimate of $0.19 million. View Eyegate Pharmaceuticals' Earnings History.
When is Eyegate Pharmaceuticals' next earnings date?
What price target have analysts set for EYEG?
1 brokers have issued 12-month target prices for Eyegate Pharmaceuticals' shares. Their predictions range from $6.00 to $6.00. On average, they expect Eyegate Pharmaceuticals' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 952.6% from the stock's current price. View Analyst Price Targets for Eyegate Pharmaceuticals.
What is the consensus analysts' recommendation for Eyegate Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyegate Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyegate Pharmaceuticals.
Has Eyegate Pharmaceuticals been receiving favorable news coverage?
Media stories about EYEG stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyegate Pharmaceuticals earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
Are investors shorting Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 1,565,000 shares, an increase of 58.4% from the September 28th total of 988,131 shares. Based on an average trading volume of 1,752,259 shares, the days-to-cover ratio is currently 0.9 days. Currently, 4.2% of the shares of the company are sold short. View Eyegate Pharmaceuticals' Current Options Chain.
Who are some of Eyegate Pharmaceuticals' key competitors?
Some companies that are related to Eyegate Pharmaceuticals include Chiasma (CHMA), CTI BioPharma (CTIC), Achaogen (AKAO), Zynerba Pharmaceuticals (ZYNE), Evofem Biosciences (EVFM), Pharmaxis (PXSLY), Fortress Biotech (FBIO), Entasis Therapeutics (ETTX), BioXcel Therapeutics (BTAI), Iterum Therapeutics (ITRM), Ophthotech (OPHT), Scpharmaceuticals (SCPH), Infinity Pharmaceuticals (INFI), Checkpoint Therapeutics (CKPT) and vTv Therapeutics (VTVT).
Who are Eyegate Pharmaceuticals' key executives?
Eyegate Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen From, Pres, CEO & Director (Age 55)
- Dr. Barbara M. Wirostko, Chief Medical Officer (Age 52)
- Mr. Michael P. Manzo, VP of Engineering (Age 59)
- Ms. Sarah Romano, Chief Financial Officer
- Mr. Mike Garanzini, Chief Commercial Officer
When did Eyegate Pharmaceuticals IPO?
(EYEG) raised $5 million in an IPO on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.
How do I buy shares of Eyegate Pharmaceuticals?
Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eyegate Pharmaceuticals' stock price today?
One share of EYEG stock can currently be purchased for approximately $0.57.
How big of a company is Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals has a market capitalization of $23.02 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 17 workers across the globe.
What is Eyegate Pharmaceuticals' official website?
How can I contact Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.
MarketBeat Community Rating for Eyegate Pharmaceuticals (NASDAQ EYEG)
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.
